Jack T Nguyen

Summary

Publications

  1. ncbi Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses
    Jack T Nguyen
    Adamas Pharmaceuticals, Inc, Emeryville, California, United States of America
    PLoS ONE 7:e31006. 2012
  2. ncbi Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro
    Jack T Nguyen
    Adamas Pharmaceuticals, Inc, Emeryville, CA 94608, USA
    Antimicrob Agents Chemother 53:4115-26. 2009
  3. ncbi Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro
    Jack T Nguyen
    Adamas Pharmaceuticals, Inc, Emeryville, California, United States of America
    PLoS ONE 5:e9332. 2010
  4. ncbi Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus
    Justin D Hoopes
    Adamas Pharmaceuticals, Inc, Emeryville, California, United States of America
    PLoS ONE 6:e29778. 2011

Collaborators

Detail Information

Publications4

  1. ncbi Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses
    Jack T Nguyen
    Adamas Pharmaceuticals, Inc, Emeryville, California, United States of America
    PLoS ONE 7:e31006. 2012
    ..These findings demonstrate in vivo efficacy of TCAD therapy and confirm previous reports of the synergy and broad spectrum activity of TCAD therapy against susceptible and resistant influenza strains in vitro...
  2. ncbi Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro
    Jack T Nguyen
    Adamas Pharmaceuticals, Inc, Emeryville, CA 94608, USA
    Antimicrob Agents Chemother 53:4115-26. 2009
    ..These data support the investigation of a novel combination of oseltamivir, amantadine, and ribavirin as an effective treatment for both seasonal and pandemic influenza virus, allowing the efficient use of the existing drug supplies...
  3. ncbi Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro
    Jack T Nguyen
    Adamas Pharmaceuticals, Inc, Emeryville, California, United States of America
    PLoS ONE 5:e9332. 2010
    ..The TCAD regimen overcomes baseline drug resistance to both classes of approved influenza antivirals, and thus may represent a highly active antiviral therapy for seasonal and pandemic influenza...
  4. ncbi Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus
    Justin D Hoopes
    Adamas Pharmaceuticals, Inc, Emeryville, California, United States of America
    PLoS ONE 6:e29778. 2011
    ..The use of mathematical modeling with multiple experimental designs and molecular readouts to evaluate and optimize combination drug regimens for the suppression of resistance may be broadly applicable to other infectious diseases...